Pliant Therapeutics (PLRX) Free Cash Flow (2019 - 2026)
Pliant Therapeutics (PLRX) posted quarterly Free Cash Flow of -$18.9 million for Q1 2026, up 61.52% year-over-year from -$11.7 million in Q1 2025, and down 8.84% quarter-over-quarter from -$17.4 million in Q4 2025.
Pliant Therapeutics (PLRX) Free Cash Flow (2019 - 2026) Analysis & Trends
Pliant Therapeutics (PLRX) has reported Free Cash Flow for 8 consecutive years, with -$18.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow rose 61.52% year-over-year to -$18.9 million; the TTM figure through Mar 2026 stood at -$98.1 million (up 44.97% YoY), while the FY2025 annual figure was -$128.3 million, up 19.49% from the prior year.
- Free Cash Flow eased to -$18.9 million in Q1 2026 per PLRX's latest filing, from -$17.4 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$17.4 million in Q4 2025 and bottomed at -$51.4 million in Q4 2024.
- Historically, Free Cash Flow has averaged -$30.6 million across 5 years, with a median of -$29.7 million in 2024.
- Annual changes were most pronounced in 2023 — Free Cash Flow slumped 105.97% — and 2025, when it surged 66.19%.
- Pliant Therapeutics' Free Cash Flow stood at -$33.0 million in 2022, then gained by 23.67% to -$25.2 million in 2023, then tumbled by 104.18% to -$51.4 million in 2024, then soared by 66.19% to -$17.4 million in 2025, then slipped by 8.84% to -$18.9 million in 2026.
- Business Quant data shows PLRX's Free Cash Flow at -$18.9 million in Q1 2026, -$17.4 million in Q4 2025, and -$21.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Pliant Therapeutics | 71.52 Mn | 71.52 Mn | - | -12.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.99 Mn |
| Jun 30, 2026 | -12.99 Mn |
| Mar 31, 2026 | -18.91 Mn |
| Mar 31, 2026 | -18.91 Mn |
| Dec 31, 2025 | -17.37 Mn |
| Dec 31, 2025 | -17.37 Mn |
| Sep 30, 2025 | -21.34 Mn |
| Sep 30, 2025 | -21.34 Mn |
| Jun 30, 2025 | -40.45 Mn |
| Jun 30, 2025 | -40.45 Mn |
| Mar 31, 2025 | -49.13 Mn |
| Mar 31, 2025 | -49.13 Mn |
| Dec 31, 2024 | -51.38 Mn |
| Dec 31, 2024 | -51.38 Mn |
| Sep 30, 2024 | -29.66 Mn |
| Sep 30, 2024 | -29.66 Mn |
| Jun 30, 2024 | -48.04 Mn |
| Jun 30, 2024 | -48.04 Mn |
| Mar 31, 2024 | -30.27 Mn |
| Mar 31, 2024 | -30.27 Mn |